ChemoCentryx, Inc.

2013 Q3 Form 10-Q Financial Statement

#000119312513332554 Filed on August 13, 2013

View on sec.gov

Income Statement

Concept 2013 Q3 2013 Q2 2012 Q2

Balance Sheet

Concept 2013 Q3 2013 Q2 2012 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $124.5M $129.8M $131.6M
YoY Change -0.8% -1.37% 81.77%
Cash & Equivalents $22.32M $50.28M $2.756M
Short-Term Investments $102.2M $79.50M $128.8M
Other Short-Term Assets $600.0K $1.000M $1.300M
YoY Change -25.0% -23.08% 44.44%
Inventory
Prepaid Expenses
Receivables $500.0K $900.0K $400.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $125.6M $131.7M $133.2M
YoY Change -0.69% -1.15% 80.0%
LONG-TERM ASSETS
Property, Plant & Equipment $1.440M $1.220M $1.300M
YoY Change 20.0% -6.15% -27.78%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $32.70M $36.60M $5.500M
YoY Change 1067.86% 565.45% -26.67%
Other Assets $160.0K $160.0K $200.0K
YoY Change -20.0% -20.0% 0.0%
Total Long-Term Assets $34.33M $37.99M $7.000M
YoY Change 737.34% 442.7% -25.53%
TOTAL ASSETS
Total Short-Term Assets $125.6M $131.7M $133.2M
Total Long-Term Assets $34.33M $37.99M $7.000M
Total Assets $160.0M $169.7M $140.2M
YoY Change 22.48% 21.01% 68.11%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $692.0K $1.198M $1.700M
YoY Change 15.33% -29.53% 240.0%
Accrued Expenses $5.004M $5.543M $4.800M
YoY Change -16.6% 15.48% -18.64%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $400.0K $500.0K $500.0K
YoY Change -20.0% 0.0% 0.0%
Total Short-Term Liabilities $6.485M $8.732M $11.50M
YoY Change -44.09% -24.07% 8.49%
LONG-TERM LIABILITIES
Long-Term Debt $100.0K $100.0K $700.0K
YoY Change -80.0% -85.71% -41.67%
Other Long-Term Liabilities $222.0K $240.0K $1.700M
YoY Change -55.6% -85.88% -74.63%
Total Long-Term Liabilities $222.0K $240.0K $2.400M
YoY Change -77.8% -90.0% -69.62%
TOTAL LIABILITIES
Total Short-Term Liabilities $6.485M $8.732M $11.50M
Total Long-Term Liabilities $222.0K $240.0K $2.400M
Total Liabilities $6.769M $9.103M $13.80M
YoY Change -46.28% -34.04% -25.41%
SHAREHOLDERS EQUITY
Retained Earnings -$163.3M -$153.9M
YoY Change
Common Stock $43.00K $43.00K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $153.2M $160.6M $126.4M
YoY Change
Total Liabilities & Shareholders Equity $160.0M $169.7M $140.2M
YoY Change 22.48% 21.01% 68.11%

Cashflow Statement

Concept 2013 Q3 2013 Q2 2012 Q2

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2013Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
42836315 shares
CY2013Q2 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
12.00
CY2012Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2756000
CY2013Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
42802917 shares
CY2013Q2 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
150000 shares
CY2013Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
42802917 shares
CY2013Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
shares
CY2013Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.00
CY2013Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4873522 shares
CY2013Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
2875061 shares
CY2013Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
1450000 shares
CY2013Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2013Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2013Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2013Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2013Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
shares
CY2013Q2 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2013Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5543000
CY2013Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
314576000
CY2013Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
1198000
CY2013Q2 us-gaap Secured Long Term Debt
SecuredLongTermDebt
131000
CY2013Q2 us-gaap Liabilities Current
LiabilitiesCurrent
8732000
CY2013Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-164000
CY2013Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
240000
CY2013Q2 us-gaap Stockholders Equity
StockholdersEquity
160553000
CY2013Q2 us-gaap Deferred Revenue
DeferredRevenue
1504000
CY2013Q2 us-gaap Secured Debt Current
SecuredDebtCurrent
487000
CY2013Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-153886000
CY2013Q2 us-gaap Common Stock Value
CommonStockValue
43000
CY2013Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
169656000
CY2013Q2 us-gaap Liabilities
Liabilities
9103000
CY2013Q2 us-gaap Long Term Investments
LongTermInvestments
36609000
CY2013Q2 us-gaap Assets Current
AssetsCurrent
131667000
CY2013Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
160000
CY2013Q2 us-gaap Assets
Assets
169656000
CY2013Q2 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
164243000
CY2013Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
50278000
CY2013Q2 us-gaap Short Term Investments
ShortTermInvestments
79493000
CY2013Q2 us-gaap Available For Sale Securities And Held To Maturity Securities
AvailableForSaleSecuritiesAndHeldToMaturitySecurities
0
CY2013Q2 us-gaap Accounts Receivable Related Parties Current
AccountsReceivableRelatedPartiesCurrent
902000
CY2013Q2 us-gaap Available For Sale Securities
AvailableForSaleSecurities
164243000
CY2013Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
994000
CY2013Q2 us-gaap Stockholders Equity Note Subscriptions Receivable
StockholdersEquityNoteSubscriptionsReceivable
16000
CY2013Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
30144051
CY2013Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
10900000
CY2013Q2 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
48141000
CY2013Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1220000
CY2013Q2 ccxi Available For Sale Securities Gross Unrealized Gain Loss Accumulated In Investments
AvailableForSaleSecuritiesGrossUnrealizedGainLossAccumulatedInInvestments
0
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
40155000
CY2012Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
36354547 shares
CY2012Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
36354547 shares
CY2012Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
shares
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.38
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5292738 shares
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
1567902 shares
CY2012Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2012Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2012Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2012Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2012Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
shares
CY2012Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2012Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6267000
CY2012Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
244513000
CY2012Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
750000
CY2012Q4 us-gaap Secured Long Term Debt
SecuredLongTermDebt
379000
CY2012Q4 us-gaap Liabilities Current
LiabilitiesCurrent
11300000
CY2012Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
2000
CY2012Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
298000
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
110346000
CY2012Q4 us-gaap Deferred Revenue
DeferredRevenue
3761000
CY2012Q4 us-gaap Secured Debt Current
SecuredDebtCurrent
522000
CY2012Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-134189000
CY2012Q4 us-gaap Common Stock Value
CommonStockValue
36000
CY2012Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
122323000
CY2012Q4 us-gaap Liabilities
Liabilities
11977000
CY2012Q4 us-gaap Long Term Investments
LongTermInvestments
16262000
CY2012Q4 us-gaap Assets Current
AssetsCurrent
104480000
CY2012Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
160000
CY2012Q4 us-gaap Assets
Assets
122323000
CY2012Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
117565000
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8460000
CY2012Q4 us-gaap Short Term Investments
ShortTermInvestments
94234000
CY2012Q4 us-gaap Accounts Receivable Related Parties Current
AccountsReceivableRelatedPartiesCurrent
1156000
CY2012Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
117565000
CY2012Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
630000
CY2012Q4 us-gaap Stockholders Equity Note Subscriptions Receivable
StockholdersEquityNoteSubscriptionsReceivable
16000
CY2012Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
7069000
CY2012Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1421000
dei Entity Registrant Name
EntityRegistrantName
ChemoCentryx, Inc.
dei Amendment Flag
AmendmentFlag
false
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2013
dei Document Type
DocumentType
10-Q
dei Document Period End Date
DocumentPeriodEndDate
2013-06-30
dei Entity Central Index Key
EntityCentralIndexKey
0001340652
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 Segment
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
159075 shares
us-gaap Nature Of Operations
NatureOfOperations
<div> <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td valign="top" width="4%" align="left"><font style="FONT-FAMILY: Times New Roman" size="2"><b>1.</b></font></td> <td valign="top" align="left"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Description of Business</b></font></td> </tr> </table> <p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">ChemoCentryx, Inc. (the Company) commenced operations in 1997. The Company is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally administered chemokine-based therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. The Company&#x2019;s principal operations are in the United States and it operates in one segment.</font></p> <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Unaudited Interim Financial Information</b></font></p> <p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">The financial information filed is unaudited. The Condensed Consolidated Financial Statements included in this report reflect all adjustments (consisting only of normal recurring adjustments) that the Company considers necessary for the fair statement of the results of operations for the interim periods covered and of the financial condition of the Company at the date of the interim balance sheet. The December&#xA0;31, 2012 Condensed Consolidated Balance Sheet was derived from audited financial statements, but does not include all disclosures required by generally accepted accounting principles in the United States of America (GAAP). The results for interim periods are not necessarily indicative of the results for the entire year or any other interim period. The Condensed Consolidated Financial Statements should be read in conjunction with the Company&#x2019;s financial statements and the notes thereto included in the Company&#x2019;s annual report on Form 10-K for the year ended December&#xA0;31, 2012 filed with the Securities and Exchange Commission, or SEC, on March&#xA0;14, 2013.</font></p> </div>
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y7M2D
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
38974000 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
13.20
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-18280000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.51
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
3.58
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
159075 shares
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y6M11D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
16234 shares
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
562057 shares
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div> <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Reclassifications</b></font></p> <p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">Certain items in the Condensed Consolidated Statements of Cash Flows have been reclassified to conform to the current fiscal year&#x2019;s format.</font></p> </div>
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
9.19
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5025194 shares
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Use of Estimates</b></font></p> <p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from these estimates.</font></p> </div>
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
194000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
364000
us-gaap Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
-254000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-19863000
us-gaap Revenue From Related Parties
RevenueFromRelatedParties
3813000
us-gaap Investment Income Interest
InvestmentIncomeInterest
226000
us-gaap Stock Issued1
StockIssued1
0
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-166000
us-gaap Repayments Of Secured Debt
RepaymentsOfSecuredDebt
283000
us-gaap Operating Income Loss
OperatingIncomeLoss
-19891000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
92045000
us-gaap Interest Paid
InterestPaid
16000
us-gaap Net Income Loss
NetIncomeLoss
-19697000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
82000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
2299000
us-gaap Costs And Expenses
CostsAndExpenses
23704000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5773000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
66693000
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
85532000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-2257000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
312000
us-gaap Share Based Compensation
ShareBasedCompensation
3094000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
41818000
us-gaap Interest Expense
InterestExpense
32000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
448000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
64365000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-6595000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17931000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-798000
us-gaap Depreciation
Depreciation
283000
ccxi Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Option Forfeited
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionForfeited
16234 shares
ccxi Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Options Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsExercised
0 shares
ccxi Non Cash Interest Income Expense Net
NonCashInterestIncomeExpenseNet
-757000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
34585000 shares
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-15195000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.58
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4703270 shares
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-486000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-60000
us-gaap Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
-130000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-19977000
us-gaap Revenue From Related Parties
RevenueFromRelatedParties
2146000
us-gaap Investment Income Interest
InvestmentIncomeInterest
270000
us-gaap Stock Issued1
StockIssued1
10215000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-1935000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
1000
us-gaap Repayments Of Secured Debt
RepaymentsOfSecuredDebt
271000
us-gaap Operating Income Loss
OperatingIncomeLoss
-19492000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
119185000
us-gaap Interest Paid
InterestPaid
28000
us-gaap Net Income Loss
NetIncomeLoss
-19978000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
69000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
196000
us-gaap Costs And Expenses
CostsAndExpenses
21638000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5035000
CY2013Q2 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
64400000
CY2012Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
36169000 shares
CY2012Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.30
CY2012Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
146000
CY2012Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10902000
CY2012Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-9000
CY2012Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-11039000
CY2012Q2 us-gaap Net Income Loss
NetIncomeLoss
-10893000
CY2012Q2 us-gaap Costs And Expenses
CostsAndExpenses
12167000
CY2012Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2473000
CY2012Q2 us-gaap Share Based Compensation
ShareBasedCompensation
900000
CY2012Q2 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
1128000
CY2012Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
167000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
56942000
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
40108000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-2146000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0
us-gaap Share Based Compensation
ShareBasedCompensation
1910000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-37399000
us-gaap Interest Expense
InterestExpense
756000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1156000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
57017000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-79146000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16603000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
124000
us-gaap Depreciation
Depreciation
311000
ccxi Non Cash Interest Income Expense Net
NonCashInterestIncomeExpenseNet
-1303000
CY2013Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
5750000 shares
CY2012Q2 us-gaap Interest Expense
InterestExpense
21000
CY2012Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9694000
CY2013Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
41337000 shares
CY2013Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.23
CY2013Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
95000
CY2013Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-9661000
CY2013Q2 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
1886000
CY2013Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
110000
CY2013Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-157000
CY2013Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-9599000
CY2013Q2 us-gaap Net Income Loss
NetIncomeLoss
-9504000
CY2013Q2 us-gaap Costs And Expenses
CostsAndExpenses
11485000
CY2013Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2809000
CY2013Q2 us-gaap Share Based Compensation
ShareBasedCompensation
1600000
CY2013Q2 us-gaap Interest Expense
InterestExpense
15000
CY2013Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8676000

Files In Submission

Name View Source Status
0001193125-13-332554-index-headers.html Edgar Link pending
0001193125-13-332554-index.html Edgar Link pending
0001193125-13-332554.txt Edgar Link pending
0001193125-13-332554-xbrl.zip Edgar Link pending
ccxi-20130630.xml Edgar Link completed
ccxi-20130630.xsd Edgar Link pending
ccxi-20130630_cal.xml Edgar Link unprocessable
ccxi-20130630_def.xml Edgar Link unprocessable
ccxi-20130630_lab.xml Edgar Link unprocessable
ccxi-20130630_pre.xml Edgar Link unprocessable
d551092d10q.htm Edgar Link pending
d551092dex311.htm Edgar Link pending
d551092dex312.htm Edgar Link pending
d551092dex321.htm Edgar Link pending
d551092dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
R1.htm Edgar Link pending
R1.xml Edgar Link unprocessable
R10.htm Edgar Link pending
R10.xml Edgar Link unprocessable
R11.htm Edgar Link pending
R11.xml Edgar Link unprocessable
R12.htm Edgar Link pending
R12.xml Edgar Link unprocessable
R13.htm Edgar Link pending
R13.xml Edgar Link unprocessable
R14.htm Edgar Link pending
R14.xml Edgar Link unprocessable
R15.htm Edgar Link pending
R15.xml Edgar Link unprocessable
R16.htm Edgar Link pending
R16.xml Edgar Link unprocessable
R17.htm Edgar Link pending
R17.xml Edgar Link unprocessable
R18.htm Edgar Link pending
R18.xml Edgar Link unprocessable
R19.htm Edgar Link pending
R19.xml Edgar Link unprocessable
R2.htm Edgar Link pending
R2.xml Edgar Link unprocessable
R20.htm Edgar Link pending
R20.xml Edgar Link unprocessable
R21.htm Edgar Link pending
R21.xml Edgar Link unprocessable
R22.htm Edgar Link pending
R22.xml Edgar Link unprocessable
R23.htm Edgar Link pending
R23.xml Edgar Link unprocessable
R24.htm Edgar Link pending
R24.xml Edgar Link unprocessable
R25.htm Edgar Link pending
R25.xml Edgar Link unprocessable
R26.htm Edgar Link pending
R26.xml Edgar Link unprocessable
R27.htm Edgar Link pending
R27.xml Edgar Link unprocessable
R28.htm Edgar Link pending
R28.xml Edgar Link unprocessable
R29.htm Edgar Link pending
R29.xml Edgar Link unprocessable
R3.htm Edgar Link pending
R3.xml Edgar Link unprocessable
R30.htm Edgar Link pending
R30.xml Edgar Link unprocessable
R31.htm Edgar Link pending
R31.xml Edgar Link unprocessable
R32.htm Edgar Link pending
R32.xml Edgar Link unprocessable
R4.htm Edgar Link pending
R4.xml Edgar Link unprocessable
R5.htm Edgar Link pending
R5.xml Edgar Link unprocessable
R6.htm Edgar Link pending
R6.xml Edgar Link unprocessable
R7.htm Edgar Link pending
R7.xml Edgar Link unprocessable
R8.htm Edgar Link pending
R8.xml Edgar Link unprocessable
R9.htm Edgar Link pending
R9.xml Edgar Link unprocessable
report.css Edgar Link pending
Show.js Edgar Link pending